Dr Reddys Laboratories (RDY) Long-Term Deferred Tax (2014 - 2026)

Dr Reddys Laboratories' Long-Term Deferred Tax history runs 13 years deep, the most recent figure standing at $245.4 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 14.83% year-over-year to $245.4 million; the TTM figure through Mar 2026 stood at $245.4 million (up 14.83% YoY), while the FY2026 annual figure was $239.0 million, up 10.14% from the prior year.
• Long-Term Deferred Tax was $245.4 million for Q1 2026 at Dr Reddys Laboratories, down from $260.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $260.4 million in Q3 2025 to a low of $87.5 million in Q1 2023.
• Historically, Long-Term Deferred Tax has averaged $164.5 million across 5 years, with a median of $131.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax slipped 25.44% in 2022, then soared 64.74% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $94.8 million in 2022, then soared by 38.24% to $131.1 million in 2023, then surged by 59.18% to $208.6 million in 2024, then climbed by 24.83% to $260.4 million in 2025, then dropped by 5.76% to $245.4 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $245.4 million (Q1 2026), $260.4 million (Q3 2025), and $213.7 million (Q1 2025), per Business Quant data.